Inicio › Linfoma folicular › Washington › Seattle
Ensayos clínicos de Linfoma folicular en Seattle, WA
16 estudios para Linfoma folicular buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- Swedish Cancer Institute (SCI), Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
ReclutandoFase 3
- Swedish Medical Center-First Hill, Seattle
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
ReclutandoFase 3
- Fred Hutch Cancer Center, Seattle
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
ReclutandoFase 1/2
- Research Site, Seattle
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
ReclutandoFase 2Se aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
ReclutandoFase 1
- Swedish Cancer Institute, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Reclutando
- University of Washington Medical Center, Seattle
Ensayos de Linfoma folicular en otras ciudades
- New York City, NY24 estudios
- Houston, TX20 estudios
- Milwaukee, WI19 estudios
- Nashville, TN18 estudios
- Baldwin Park, CA16 estudios
- Boston, MA16 estudios
- Durham, NC16 estudios
- Salt Lake City, UT13 estudios
- Columbus, OH13 estudios
- Los Angeles, CA13 estudios
- Chicago, IL12 estudios
- San Antonio, TX12 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer (todos los tipos)48 estudios
- Cáncer de próstata45 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer metastásico39 estudios
- Cáncer de seno37 estudios
- Cáncer del colon y del recto35 estudios
- Cáncer de pulmón34 estudios
- Cáncer de ovario29 estudios
- Cáncer de páncreas22 estudios
- Mieloma múltiple22 estudios
- Leucemia linfoblástica aguda22 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.